Novan Inc represents values of innovation, commitment, and excellence in the pharmaceutical industry. The company's corporate philosophy centers around developing novel therapies to improve the lives of patients. Novan Inc is dedicated to advancing dermatology treatments through its unique nitric oxide platform. By harnessing the potential of nitric oxide, the company aims to address unmet medical needs and deliver effective solutions for various skin conditions. Novan Inc's strong focus on research and development, combined with a patient-centric approach, drives its mission to make a positive impact on healthcare outcomes.

Novan Inc primarily operates within the United States.

Novan Inc, a leading pharmaceutical company, has accomplished several significant milestones. Firstly, the company received FDA approval for their breakthrough drug, SB204, for the treatment of acne vulgaris. Moreover, Novan Inc successfully completed phase 3 clinical trials for Nitric Oxide-releasing product candidates, showcasing promising results for various dermatological conditions. Additionally, Novan Inc forged strategic partnerships with renowned pharmaceutical organizations to enhance their market presence and expand their research and development capabilities. These accomplishments demonstrate Novan Inc's commitment to innovation and advancement in the medical field, solidifying their position as a key player in the healthcare industry.

Novan Inc is a leading biotechnology company that specializes in developing innovative therapies to address unmet medical needs. Established in [year], Novan Inc has been committed to advancing the field of dermatology. The company focuses on utilizing nitric oxide technology to create novel medications for various skin conditions. With a talented team of researchers and scientists, Novan Inc is dedicated to improving patient care and quality of life. Leveraging cutting-edge research, Novan Inc continues to pave the way for groundbreaking dermatological treatments. Their commitment to innovation and passion for dermatology has positioned them as a key player in the biotechnology industry.

The main competitors of Novan Inc in the market are [competitor 1], [competitor 2], and [competitor 3].

Novan Inc is primarily active in the pharmaceutical industry.

Novan Inc operates with a biotechnology business model. The company develops and commercializes innovative therapies using its nitric oxide platform. Novan focuses on addressing various dermatological and healthcare conditions by leveraging the potential of nitric oxide for local treatment. Through their research and development efforts, Novan aims to provide effective and advanced solutions for dermatological conditions such as acne, fungal infections, and inflammatory skin diseases. With a strong focus on utilizing their proprietary technology, Novan Inc strives to improve patients' lives by delivering innovative nitric oxide-based treatments for various medical needs.

Poměr Novan P/E je 0,11.

Koeficient Novan tržních hodnot je 0,01.

AlleAktien kvalitní skóre pro Novan je 2/10.

očekávané Novan obrat je 106,42 mil. USD.

očekávané Novan zisk je 5,42 mil. USD.

Novan Inc. is an innovative biopharmaceutical company specializing in the development of new therapeutic approaches for the treatment of skin diseases. The company has been listed on NASDAQ since 2006 and is headquartered in Morrisville, North Carolina, USA. Novan has a wide portfolio of products that help alleviate or heal skin problems. It is divided into three divisions: dermatology, oncology, and wound healing. In the dermatology division, Novan specializes in the treatment of acne, rosacea, and other skin diseases. The company uses a technology called Nitrotop, which optimizes the oxygen supply to the skin cells, to improve skin problems. By improving cell metabolism, healing is accelerated and skin regeneration is supported. One of the most promising applications of Nitrotop is currently in the clinical testing phase and has the potential to become a new therapy for the treatment of shingles. In the oncology division, Novan is working to improve the treatment of skin tumors. The company uses a therapy called SB4144, which contains an innovative combination of active ingredients that specifically target tumor cells. Novan has already achieved promising results and will continuously conduct further studies to improve the effectiveness of the therapy. Wound healing is another important focus for Novan. The company is developing new wound dressings based on the Nitrotop technology. These dressings can help accelerate wound healing and prevent infections. In addition to these three focuses, Novan is also working on a new generation of sunscreen products that improve UV protection and support skin care. To further develop its products, the company collaborates closely with academics, governmental agencies, and other pharmaceutical companies. Novan has also formed partnerships with renowned companies in the industry, such as Johnson & Johnson and Galderma. As part of its business strategy, Novan relies on a broad diversification of its products and services. The company places great emphasis on research and development and continuously invests in new technologies and patents. Novan also emphasizes close collaboration with its customers and patients to better understand their needs and expectations. As an innovative company, Novan also focuses on a strong online presence and intensive marketing to promote its products. The company attaches great importance to creating brand awareness and fostering trust among its customers. In summary, Novan Inc. is a significant biopharmaceutical company specializing in the development of new therapeutic approaches for the treatment of skin diseases. The company has a wide portfolio of products and services aimed at improving or healing skin problems. Novan relies on broad diversification and continuous investment in research and development.

Novan vyplácí dividendu ve výši 0 USD rozdělenou do výplat během roku.

Dividenda pro Novan momentálně nemůže být vypočítána nebo společnost žádnou dividendu nevyplácí.

ISIN společnosti Novan je US66988N1063.

WKN společnosti Novan je A2AR9U.

Ticker společnosti Novan je NOVN.

Během posledních 12 měsíců vyplatila společnost Novan dividendu ve výši . To odpovídá dividendovému výnosu přibližně . Pro nadcházejících 12 měsíců se očekává, že Novan vyplatí dividendu ve výši 0 USD.

Výnos z dividend společnosti Novan aktuálně činí .

Novan vyplácí čtvrtletní dividendu. Ta je distribuována v měsících .

Novan vyplácela v posledních 0 letech každý rok dividendu.

Očekává se, že v následujících 12 měsících budou dividendy ve výši 0 USD. To odpovídá dividendovému výnosu 0 %.

Novan je přiřazen k sektoru 'Zdraví'.

Aby ses mohl podílet na poslední dividendě Novan ve výši 0 USD, zaznamenané 18. 1. 2025, měl jsi mít akcii ve svém portfoliu před ex-dnem 18. 1. 2025.

Poslední dividendy byly vyplaceny dne 18. 1. 2025.

V roce 2024 společností Novan bylo vyplaceno 0 USD ve formě dividend.

Dividendy společnosti Novan jsou vypláceny v USD.